Alpha Cognition (ACOG) Stock Price, News & Analysis

Company Overview

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $8.50 to $9.40
• 50-Day Range: $4.12 to $10.57
• 52-Week Range: $3.75 to $11.40
• Volume: 30,155 shs
• Average Volume: 99,315 shs
• Market Capitalization: $140.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Alpha Cognition Stock Analysis - MarketRank™

Alpha Cognition scored higher than 32% of companies evaluated by MarketBeat, and ranked 2152nd out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Alpha Cognition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alpha Cognition has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Cognition is -7.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Cognition is -7.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Cognition has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACOG.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Cognition does not currently pay a dividend.

Dividend Growth

Alpha Cognition does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ACOG.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Alpha Cognition has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alpha Cognition this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ACOG on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Alpha Cognition to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alpha Cognition insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.00% of the stock of Alpha Cognition is held by insiders. A high percentage of insider ownership can be a sign of company health.

ACOG Stock Analysis - Frequently Asked Questions

How have ACOG shares performed this year?

Alpha Cognition's stock was trading at $5.86 at the start of the year. Since then, ACOG stock has increased by 49.8% and is now trading at $8.78.
View the best growth stocks for 2025 here.

How were Alpha Cognition's earnings last quarter?

Alpha Cognition Inc. (NASDAQ:ACOG) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.38. The firm had revenue of $2.93 million for the quarter, compared to analysts' expectations of $0.50 million.
Read the conference call transcript.

When did Alpha Cognition IPO?

Alpha Cognition (ACOG) raised $50 million in an initial public offering on Tuesday, November 12th 2024. The company issued 8,695,653 shares at a price of $5.75 per share.

When did the company's lock-up period expire?

Alpha Cognition's lock-up period expired on Monday, May 12th. Alpha Cognition had issued 8,695,653 shares in its IPO on November 12th. The total size of the offering was $50,000,005 based on an initial share price of $5.75. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Alpha Cognition's major shareholders?

Alpha Cognition's top institutional shareholders include AWM Investment Company Inc. (6.84%), Alyeska Investment Group L.P. (2.11%), Altium Capital Management LLC (1.11%) and Corsair Capital Management L.P. (0.88%).

How do I buy shares of Alpha Cognition?

Shares of ACOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/19/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACOG
• CIK: 1655923
• Web: N/A
• Phone: (858) 344-4375
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.00
• High Stock Price Target: $20.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +123.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.64 million
• Net Margins: N/A
• Pretax Margin: -397.44%
• Return on Equity: -65.83%
• Return on Assets: -48.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.14
• Quick Ratio: 16.83

Sales & Book Value

• Annual Sales: $2.93 million
• Price / Sales: 48.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 3.45

Miscellaneous

• Outstanding Shares: 16,020,000
• Free Float: 13,777,000
• Market Cap: $143.22 million
• Optionable: N/A
• Beta: 2.79